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ABSTRACT
Ischaemic brain injuries are rare con-
ditions in the paediatric age group. 
Main causes include non-arterioscle-
rotic arteriopathies, which in child-
hood usually result from primary 
vasculitis of large or small vessels 
and lead to impaired perfusion and 
subsequent ischaemic brain lesions. 
In accordance with the nomenclature 
of systemic forms, CNS vasculitis is 
subdivided into groups, based on the 
size of affected vessels: angiography-
positive primary angiitis of medium 
sized and large vessels (pPACNS), and 
angiography-negative angiitis of small 
vessels (svPACNS).
We report the clinical presentation, di-
agnostic approach, and therapy of four 
children with progressive pPACNS. Pa-
tients were treated with high-dose cor-
ticosteroids and anticoagulation with 
unfractionated heparin in the acute 
phase, followed by immune modulatory 
treatment with mycophenolate mofetil 
(MMF) and dual antiplatelet therapy 
with acetylsalicylic acid and clopi-
dogrel. In this manuscript, we illustrate 
the experience gained in our hospital, 
resulting in significantly faster diag-
nosis and treatment initiation, and dis-
cuss the applied immune modulating 
treatment regimen in the context of the 
literature. Based on our observations, 
we conclude that immune modulating 
therapy with initial high-dose corti-
costeroids, followed by steroid-sparing 
maintenance treatment with MMF, may 
be safe and effective in childhood pro-
gressive pPACNS.
Introduction
Ischaemic brain injury is a rare but 
severe condition in the paediatric age 
group. According to epidemiologic 
data from the USA, the incidence of 
acute ischaemic stroke (AIS) in child-
hood exceeds 3.3/100 000 children 
per year (1). Recurrence rates vary be-
tween 5% and 25% (2, 3). Diagnosis 
and management can be challenging 
due to the rarity of pediatric AIS, dif-
ferential diagnoses (“stroke mimics”), 
and the absence of uniformly accepted 
diagnostic and therapeutic guidelines.
Though non-arteriosclerotic artherio-
pathies are the most common cause of 
childhood AIS after the neonatal period 
(4), their pathophysiology is poorly un-
derstood. As a result, nomenclature of 
underlying conditions is inconsistent 
and varies between the neuropediat-
ric and the rheumatological literature. 
“Cerebral artheriopathy” is a descrip-
tive diagnosis (5) that, after the ex-
clusion of differential diagnoses (e.g. 
fibromuscular dysplasia), can be nar-
rowed down to “inflammatory artherio-
pathies”, which can be subdivided into 
primary and secondary CNS vasculi-
tis (6, 7). Criteria for the diagnosis of 
childhood primary angiitis of the cen-
tral nervous system (PACNS) include 
i) an acquired neurological deficit, ii) 
angiographic or histological features 
of vasculitis, iii) the absence of an al-
ternative explanation of the symptoms, 
and iv) new-onset psychiatric deficits 
(8).
Clinical presentations of PACNS are 
variable, and, among other factors, 
depend on the size and location of the 
affected vessels, individual host fac-
tors, and severity and duration of the 
inflammatory response. In accordance 
to primary systemic vasculitis, PACNS 
is stratified depending on the size of 
affected vessels (7, 9). Large and me-
dium sized vessel primary CNS vascu-
litis is referred to as angiography-posi-
tive (pPACNS), small vessel disease as 
angiography-negative svPACNS (9).
Angiography-positive PACNS is fur-
ther divided into monophasic non-
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progressive forms, also referred to as 
transient cerebral arteriopathy (TCA), 
and progressive forms (10). Patients 
with transient pPACNS/TCA typically 
present with focal neurological defi-
cits, headaches and/or encephalopathy, 
depending on the vessel affected. Tran-
sient pPACNS/TCA is characterized by 
unilateral focal or segmental stenosis 
or occlusion involving the distal part of 
the internal carotid artery, and proximal 
segments of the anterior and/or middle 
cerebral artery (11). Historically, non-
progressive pPACNS/TCA was defined 
by stable or regressing arterial changes 
in follow-up imaging studies 6 months 
after disease onset when compared to 
MRI angiograms at 3 months (12). 
Other patients develop chronically ac-
tive CNS vasculitis, which can result in 
a series of ischemic strokes and even 
more severe sequelae. In such cases, 
the term progressive pPACNS is used. 
Recent reports suggest clinical features 
and vessel involvement on MR angio-
grams as early predictors of disease 
course, allowing timely and adequate 
treatment, preventing long-term dis-
ease activity (13). Clinical hallmarks 
of progressive pPACNS are focal and 
additional diffuse neurological deficits, 
with headaches, cognitive dysfunction, 
seizures, and encephalitis-like symp-
toms frequently preceding focal neuro-
logical deficits. Progressive pPACNS 
is characterized by uni- or bilateral fo-
cal or segmental stenosis or occlusion, 
involving the proximal and/or distal 
part of the internal carotid artery, and 
proximal and/or distal segments of the 
anterior and/or middle cerebral artery, 
as well as the posterior arteries (14). 
Provided timely diagnosis and treat-
ment initiation, disease progression 
should be avoided and may not be seen 
in adequately treated patients with oth-
erwise “progressive” disease (15). We 
present the clinical course and disease 
outcomes in four children with pro-
gressive pPACNS, some of whom were 
diagnosed and treated early during dis-
ease, others after prolonged symptoms 
and/or relapses. Focusing on clinical 
presentation, diagnostic and therapeu-
tic approaches, as well as disease out-
comes in the context of the available 
literature, this report emphasizes the 
importance of PACNS treatment in ex-
perienced multi-professional teams as 
well as the establishment of consensus 
diagnostic and therapeutic regimens.
Methods
Medical charts of four pediatric pa-
tients with progressive pPACNS were 
reviewed to collect clinical and labo-
ratory data at the time of diagnosis, 
applied treatment, and neurological 
outcomes after 18-42 months. Clinical 
presentation and response to treatment 
were evaluated in the context of avail-
able literature.
Case reports
All four reported patients originate 
from non-consanguineous Caucasian 
families with no history of clotting dis-
orders or stroke episodes in the family 
or personal history.
Case 1
An 8-year-old, previously healthy boy 
presented with headaches, fatigue, 
aphasia, ataxia, and progressive ver-
tigo (Table I). Magnetic resonance im-
aging (MRI) three days after the onset 
of symptoms revealed a stenosis of the 
distal basilar artery with concomitant 
alterations in proton diffusion capacity 
in the cerebellum (Fig. 1A, C). Due to 
a suspected diagnosis of thromboem-
bolic ischemic insult, the patient was 
started on therapeutic doses of unfrac-
tionated heparin (UFH). Neurological 
deficits regressed over the course of 
6 days, and treatment was switched 
to acetylsalicylic acid (ASA, 1.4 mg/
kg/d). After 9 days, the patient relapsed 
with symptoms of double vision, nau-
sea, and emesis. Magnetic resonance 
imaging revealed progressive stenosis 
of the proximal and distal basilar ar-
tery, with new areas of altered diffusion 
capacity in the left cerebellum (Fig. 1 
B, D); heparin was re-introduced. Af-
ter another 18 days, the boy presented 
with new symptoms of ataxia and em-
esis; MRI unveiled an almost complete 
occlusion of the basilar artery and new 
parenchymal lesions with altered pro-
ton diffusion (Fig. 1E, F). Local throm-
bolysis was performed with recombi-
nant tissue plasminogen activator (rt-
PA), followed by temporary stenting 
and mechanical thrombectomy. After 
the intervention, the patient was started 
on a dual anti-platelet-therapy with 
ASA (2 mg/kg/d) and clopidogrel (0.5 
mg/kg/d).
Because of the presence of general 
symptoms, the long segment involve-
ment of proximal and distal cerebral 
vessels, together with the rapidly re-
lapsing character, the diagnosis pro-
gressive pPACNS was made, and the 
patient was started on oral prednisolone 
(2 mg/kg/d) on day 29. Steroid-sparing 
mycophenolate mofetil (MMF) treat-
ment was initiated (1000 mg/m2/d), and 
corticosteroids were slowly tapered 
over three months (Table II). After the 
Table I. Patient characteristics.
Patient No. 1 2 3 4
Age at onset (years) 8 9 9 3,5
Gender male male female female
Clinicalsymptoms headache, progressive hemiparesis, hemiparesis,
 aphasia, hemiparesis, facial nerve ataxia,
 ataxia, aphasia, palsy, vomiting slurred speech 
 vertigo anisocoria, 
  somnolence  
 
Time to admission 3 days 1 day 2 days 3 weeks 
    (from first symptoms) 
Time to anti-coagulation 3 days 1 day 2 days 3 weeks 
    (from first symptoms) 
Time to immune modulation 29 days 17 days 4 days 4 days, 
    with corticosteroids    (approximately 
    (from admission)     25 days from  
    first symptoms)
Number of ischemic events 3 3 1 (+ 1 TIA) 1
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introduction of immune modulating 
treatment, no additional relapses oc-
curred, and follow-up MR imaging, 12 
months after the first ischemic attack 
revealed a normal configuration of the 
basilar artery. MMF treatment was dis-
continued after 18 months, while ASA 
treatment was continued because of 
persisting mild obstruction of the left 
vertebral artery. Minor impairment of 
fine motor skills of the upper limb and 
attention deficits remained.
Case 2 
A nine-year-old, previously healthy 
boy presented with progressive hemi-
paresis on the right, anisocoria, hypo-
glossus and facial nerve palsy on the 
left, aphasia, somnolence, and emesis 
Fig. 1. MRI findings in an 8-year old boy with PACNS. Upper panel: Axial diffusion weighted imaging (DWI, b=1000s/mm²), showing bilateral cerebel-
lar lesions with reduced diffusivity with high intensity (*). Lower panel: Maximum intensity projection (MIP) of 3 dimensional time-of-flight (TOF) MR 
angiogram, showing progressive occlusion of the basilar artery (→). MRI imaging performed on A, C) day 6, B, D) day 9, and C, E) day 18 after the onset 
of symptoms.
Table II. Treatment and response.
Patient No. 1 2 3  4
Initial Anti-coagulation UFH (550 IE/kg/d) UFH (470 IE/kg/d)  UFH (360 IE/kg/d) UFH (500IE/kg/d)
Antiplatelet therapy ASA (2 mg/kg/d) ASA (3 mg/kg/d) ASA (2.7 mg/kg/d)  ASA (3 mg/kg/d)
 clopidogrel clopidogrel  clopidogrel clopidogrel
 (0.5 mg/kg/d) for 6 months (0.5 mg/kg/d) for 6 months (0.6 mg/kg/d) for 6 months (1 mg/kg/d) for 6 months
Immune modulation Prednisolone Methyl-prednisolone Methyl-prednisolone Methyl-prednisolone
 (2 mg/kg/d p.o.) for 2 months,  (20 mg/kg/d i.v. for 5 days) (20 mg/kg/d i.v. for 5 days) (20 mg/kg/d i.v. for 5 days)
 followed by tapering over 4   followed by Prednisolone 
 weeks    (2 mg/kg/d p.o.) for 3 months
 MMF MMF MMF MMF
 900 mg/m2/d p.o. for 18 1100 mg/m2/d p.o. for 18 1000 mg/m2/d p.o. for 18 1000 mg/m2/d p.o. for 15 
 months months months  months (to date)
Follow-up 48 months 42 months 30 months 15 months
Clinical outcome Minor impairment of fine Incomplete hemiparesis on Mild paresis of the right hand,  Mild paresis of the right
 motor skills on the upper limb, the right, attention deficit and attention deficit, reduced  hand (mild pre-existing
 attention deficit reduced working memory retentiveness speech disorder)
UFH: unfractionated heparin; LMWH (enoxaparin): low molecular weight heparin; ASA: acetyl salicylic acid; MMF: mycophenolate mofetil.
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(Table I). Brain MRI one day after the 
onset of symptoms revealed reduced 
proton diffusion capacity in the right 
thalamus region, in the pons cerebri, 
paramedian white matter, and cerebel-
lum (Fig. 2A). In time of flight (TOF) 
angiography MRI sequences, almost 
complete occlusion of the basilar ar-
tery, and thinning of the right vertebral 
artery secondary to vessel wall edema 
were detected. The patient was started 
on UFH treatment. After six days, the 
boy developed clinical improvement of 
both the hemiparesis and the aphasia. 
Thus, heparin was replaced with ASA 
(3 mg/kg/d). However, three days lat-
er, neurological symptoms worsened, 
with the patient exhibiting progressive 
hemiparesis. MR imaging revealed 
new ischemic lesions in the left cer-
ebellum. Thus, heparin treatment was 
re-established. Despite anticoagula-
tion, the patient developed vertigo, 
nausea, vomiting, and spontaneous 
nystagmus. Magnetic resonance imag-
ing revealed additional hypoperfusion 
areas in the pons cerebri.
Because of the presence of general 
symptoms, the long segment involve-
ment of proximal and distal cerebral 
vessels with contrast enhancement in 
T1 sequences, together with the rap-
idly relapsing character, the diagnosis 
childhood progressive pPACNS was 
made on day 17 after the onset of first 
symptoms. Treatment with methyl-
prednisolone i.v. pulses (20 mg/kg/d) 
was initiated over five days, and MMF 
was started as steroid-sparing treat-
ment (1000 mg/m2/d) (Table II). Seven 
days after the last relapse, antiplatelet-
therapy was expanded with clopidogrel 
(0.5 mg/kg/d), and heparin treatment 
was tapered and finally discontinued. 
A follow-up MRI, six months after the 
initial manifestation, revealed a stable 
situation. Clopdiogrel was discontin-
ued after nine months, MMF was dis-
continued after 18 months, while ASA 
is still administered. To date, no further 
relapse occurred (in 42 months). While 
the boy retained a mild hemiparesis on 
his right side as well as attention deficit 
and reduced working memory, he at-
tends a regular school. 
Case 3 
A nine-year-old, previously healthy 
girl presented with a two-day history of 
severe headaches, nausea, and emesis 
(Table I). Additionally, she exhibited 
acute dysphasia, facial nerve palsy, and 
hemiparesis of her left upper and lower 
extremities. Magnetic resonance imag-
Fig. 2. MRI findings in a 9-year old boy with PACNS, 1 day after the onset of symptoms. Axial diffusion weighted imaging (DWI, b=1000s/mm²), showing 
fresh lesions in the left pons region with reduced diffusion (*) in A), and older lesions in the basal ganglia on the right (→) in B). C) Maximum intensity 
projection (MIP) of 3 dimensional time-of-flight (TOF) MR angiogram, unveiling an occlusion of the basilar artery (→).
Fig. 3. MRI findings in a 9-year old girl with PACNS, 2 days after the onset of symptoms. A) Axial 
diffusion weighted imaging (DWI, b=1000s/mm²), showing fresh lesions in the right frontoparietal 
region with reduced diffusivity (*). B) Single image from 3 dimensional time-of-flight (TOF) and C) 
Maximum intensity projection (MIP) of 3D time-of-flight (TOF) angiogram, unveiling an occlusion 
and stenosis of the right internal carotid artery (→). In C) arterial wall thickening of the right internal 
carotid artery with luminal obstruction can be seen (↓).
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ing 2 days after the onset of symptoms 
revealed reduced proton diffusion ca-
pacity of the right cortical hemisphere, 
reflecting parenchymal damage due 
to an occlusion of the internal carotid 
artery distal to the posterior communi-
cating artery, as seen on TOF angiogra-
phy MRI (Fig. 3 B, C). The patient was 
started on therapeutic doses of UFH. 
On day 4, the girl developed clinical 
progression of hemiparesis, slurred 
speech, and a decline in vigilance. The 
subsequent brain MRI did not reveal 
new brain lesions, but signs of large 
vessel inflammation, including arterial 
wall thickening, and contrast enhance-
ment. Provided general symptoms and 
the long segment involvement of the 
arteria cerebri interna, the diagnosis 
progressive pPACNS was made.
Methylprednisolone i.v. pulses (20 mg/
kg) were given over five days, and the 
patient was started on steroid-sparing 
immunomodulatory treatment with 
MMF (1000mg/m2/d) for 18 months 
(Table II). After twelve days, heparin 
treatment was tapered to a prophylactic 
dose for an additional five days, over-
lapping dual anti-platelet-therapy with 
clopidogrel (0.5 mg/kg/d) and ASA 
(2.7 mg/kg/d). To date, no further clini-
cal relapse occurred (30 months). The 
patient has a mild paresis of the right 
hand as well as attention deficits and 
impaired memory. Follow-up MRIs re-
vealed complete resolution of inflam-
mation, while arterial wall-thickening 
remained (Fig. 3).
Case 4 
A three and a half year-old girl present-
ed with progressive paresis of the right 
arm, ataxia, and slurred speech that 
had started approximately three weeks 
prior to admission (Table I). Patient’s 
prior history included delayed speech 
development.
While all aforementioned patients had 
been vaccinated according to national 
recommendations, the child had suf-
fered a wild-type varicella infection 
about six months prior to admission. 
Magnetic resonance imaging at admis-
sion indicated pre-existing and recent 
infarctions in the left hemisphere. Al-
tered proton diffusion capacity (Fig. 
4A), reduced vessel calibers on TOF 
angiography (Fig. 4B), and contrast 
enhancement in T1 sequences with fat 
saturation (Fig. 4C) suggested vascu-
litis of the left internal carotid artery, 
mid-cerebral artery, and anterior cere-
bral artery. Ultrasound examination un-
veiled pathological intima thickening 
of the common carotid and left internal 
carotid artery. Provided the rapidly pro-
gressing symptoms and long segment 
involvement of proximal and distal 
cerebral vessels, the diagnosis progres-
sive pPACNS was made. The girl was 
started on therapeutic UFH treatment 
and ASA (3 mg/kg/d). Four days after 
initiation of heparin treatment, it was 
replaced with clopidogrel (1 mg/kg/d). 
Methylprednisolone i.v. pulses (20 mg/
kg/d) were given for five days, fol-
lowed by oral prednisolone (tapering 
over three months), and immunomodu-
latory treatment with MMF (1000 mg/
m2/d) (Table II). Over the observation 
period of 15 months, no relapses oc-
curred. In addition to the pre-existing 
mild speech disorder, a mild paresis of 
the right hand remained.
Discussion
In contrast to adults, acute ischaemic 
stroke (AIS) is a rare entity in child-
hood (1). Furthermore, the pathophysi-
ology in paediatric AIS often differs 
from adults, with vasculitic lesions 
being the most frequent cause after the 
neonatal period. In concordance with 
Fig. 4. MRI findings in a 3.5-year old girl with PACNS, approximately three weeks after onset of 
first symptoms. A) Axial diffusion weighted imaging (DWI, b=1000s/mm²), showing fresh lesions 
in the left basal ganglia with reduced diffusivity (*). B) Single image from 3D time-of-flight (TOF) 
angiogram and C) Maximum intensity projection (MIP) of 3D time-of-flight (TOF), unveiling an ob-
struction and stenosis of the left internal carotid artery (arrows). D) Transversal gadolinium enhanced 
T1 sequences with fat saturation unveiled contrast enhancement of the prominent arterial wall as a sign 
of vasculitis (arrow).
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the nomenclature in systemic disease, 
primary angiitis of the CNS (PACNS) 
requires differentiation from second-
ary causes, which include infections, 
inflammatory and non-inflammatory 
collagen vascular diseases, and malig-
nancies (16, 17). Here, we report four 
exemplary cases of progressive pPAC-
NS in childhood; two in boys and two 
in girls. While our small cohort exhib-
its equal gender distribution, typically 
a male preponderance is observed in 
childhood pPACNS (f:m=2:3) (17).
Important differential diagnoses to 
childhood PACNS include inflamma-
tory conditions secondary to other in-
flammatory and/or non-inflammatory 
CNS or systemic diseases (including 
infections), such as primary or sec-
ondary systemic vasculitis with CNS 
involvement (e.g. SLE, Takayasu ar-
teritis, etc.), Moyamoya syndrome, fi-
bromuscular dysplasia, arterial dissec-
tions, and others (17-19). 
Of note, a significant subset of patients 
with transient pPACNS/TCA exhibit a 
history of varicella zoster virus (VZV) 
infections within 12 months prior to 
disease-onset (up to 50%), suggest-
ing a pathophysiological link between 
VZV infections and pPACNS (15, 18). 
To our knowledge, reliable data on 
concurrent or recent VVZ infection 
rates do not exist for progressive forms 
of pPACNS (case 4 in this report). 
Though the pathophysiological role of 
VZV in pPACNS has not been scientifi-
cally proven, high rates of recent infec-
tions suggest an involvement at least 
in non-progressive forms of pPACNS. 
Thus, in such cases, the term “primary 
angiitis” may be considered somewhat 
incorrect. In line with the existing lit-
erature, the pathophysiological role of 
a previous VZV infection 6 months 
prior to disease-onset in Case 4 re-
mains unclear. In the presented patient, 
particularly since clinical presentation 
and MRI angiography were indicative 
for progressive pPACNS, VZV was not 
treated with acyclovir, and the patient 
responded to induction therapy with 
high-dose corticosteroids followed by 
maintenance treatment with MMF.
Transient pPACNS/TCA is generally 
considered a self-limiting condition, 
and some authors even argue that in-
dividual patients may not require im-
mune suppressive or modulating treat-
ment at all. Though the inflammatory 
phase of non-progressive pPACNS/
TCA is transient, almost 60% of chil-
dren with AIS develop permanent neu-
rological or neurocognitive deficits, 
and almost 80% retain residual arterial 
lesions (15). At the time of manifesta-
tion, differentiation between progres-
sive and transient pPACNS can be dif-
ficult. However, depending on the pat-
tern of affected vessels and resulting 
clinical symptoms, individuals with 
transient disease may be distinguished 
from such individuals at the beginning 
of a progressive disease course. Tran-
sient pPACNS is characterized by short 
segment involvement of a single artery. 
Thus, most patients with monopha-
sic pPACNS/TCA present with focal 
neurological deficits, sometimes head-
aches, and/or encephalopathy depend-
ing on the area affected. Conversely, 
patients with progressive PCANS 
exhibit long segment involvement of 
proximal and distal cerebral vessels, 
more severe systemic symptoms, and 
sometimes elevated systemic inflam-
matory markers (in up to 50%) (6, 8, 9, 
12, 13). Because of the rapidly progres-
sive character in the presented cases, 
long segment involvement of proximal 
and distal segments of the affected ves-
sels, the diagnosis progressive pPAC-
NS was made, and all patients were 
treated accordingly.
As childhood AIS is rare, treatment ap-
proaches in childhood pPACNS vary 
significantly throughout the literature. 
Reported strategies include acute phase 
and maintenance treatment. In the acute 
phase, depending on the time-line and 
duration of symptoms, mechanical 
thrombectomy or thrombolysis may 
be discussed in individual cases. How-
ever, provided the lack of experience 
in the pediatric age group, neither ap-
proach is generally recommended 
outside of specific research protocols. 
In one of the here reported patients 
(case 1), mechanical thrombectomy 
and temporary stent implantation was 
performed, as the basilar artery was oc-
cluded (19). Anticoagulant treatment 
is based on the actual guidelines of the 
American College of Chest Physicians 
and includes unfractionated heparin, 
low molecular weight heparin or ASA, 
followed by anti-platelet therapy with 
ASA or clopidogrel for a minimum of 
two years (19). 
Controlling inflammation is central for 
preventing disease progression and im-
proving disease outcomes. However, 
evidence-based and/or widely accepted 
protocols for anti-inflammatory or im-
mune modulating treatment of tran-
sient or progressive pPACNS are lack-
ing. Applied regimens for induction 
treatment include methylprednisolone 
i.v. pulses or oral corticosteroids, both 
followed by tapering strategies (usu-
ally over 3-6 months), and cyclophos-
phamide i.v. every 4 weeks for up to 6 
months (8). For maintenance treatment, 
low-dose corticosteroids, MMF, or oth-
er purine- or pyrimidine antagonists are 
discussed (8). All of the here reported 
pPACNS patients were diagnosed with 
progressive disease, and treated with 
anticoagulatory agents, corticosteroids, 
and MMF. Three children suffered re-
curring brain ischemia under exclu-
sive anticoagulation treatment prior to 
the initiation of immune modulation. 
In our institution, patients diagnosed 
with progressive pPACNS are usually 
treated with high-dose methylpredni-
solone i.v. pulses (20-30 mg/kg/d) to 
impede acute inflammatory responses, 
followed by oral corticosteroids for 
3-6 months, and immune modulatory 
treatment with MMF in combination 
with dual antiplatelet therapy (with 
ASA and clopidogrel). All of the here 
reported patients remained relapse free 
after the initiation of immune modula-
tory treatment. 
However, in two children (cases 1 and 
2), the diagnosis progressive PACNS 
was only made after several relapses, 
and patients would potentially have 
benefitted from an earlier introduction 
of anti-inflammatory treatment. The re-
duced “time to correct diagnosis” and 
subsequent treatment initiation in the 
here presented cases, together with im-
proved outcomes of pPACNS patients 
indicate a learning curve in our institu-
tion and the interdisciplinary approach. 
Thus, in our (and other authors’) opin-
ion, the diagnosis progressive pPACNS 
should not be solely based on the pro-
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gression of inflammatory lesions over 
6 months, but rather on clinical symp-
toms, laboratory tests, and vasculopa-
thy patterns on MRI (6, 8, 9, 12, 13). 
Furthermore, high-dose corticosteroid 
treatment should at least be considered 
in all pPACNS patients to rapidly con-
trol inflammatory activity and prevent 
(progressive) vascular stenosis (Fig. 5).
After the initiation of immune modula-
tory treatment with corticosteroids and 
MMF, all of our cases achieved stable 
remission without further relapses. 
Thus, it is worth discussing whether 
cyclophosphamide, which is suggested 
by some authors (6, 8), is necessary for 
the treatment of progressive pPACNS. 
Based on our (certainly limited) ex-
perience, high-dose corticosteroids 
for remission induction, followed by 
MMF as maintenance treatment may 
be sufficient at least in most cases. To 
finally answer the question of which 
treatment option may be the safest and 
most effective alternative in individual 
PACNS patients, randomized prospec-
tive multi-center studies are necessary 
to determine optimal treatment with 
minimal treatment-associated side-ef-
fects. However, it may prove difficult 
to identify and recruit sufficient num-
bers of patients in this rare and variable 
entity. 
A particular challenge in individual 
patients can be the prediction of clini-
cal courses, distinguishing between 
transient or progressive PACNS. Since 
short-term corticosteroid treatment and 
immune modulation with MMF are 
usually tolerated without severe long-
term sequelae, while ischemic stroke 
may affect an individual’s further de-
velopment, cognitive, and/or motor 
skills, we argue to initially treat all 
pPACNS patients, including those with 
both transient and progressive disease, 
with corticosteroids, and to include 
steroid-sparing agents, such as MMF, 
in cases suggestive of progressive dis-
ease (6, 8) (Fig. 5).
Conclusions
Paediatric primary angiitis of the CNS 
(pPACNS) are rare disorders, but ac-
count for a large portion of ischemic 
brain injuries in childhood. Outcomes 
depend largely on a timely and correct 
diagnosis, ensuring sufficient treatment 
to prevent disease progression and/or 
relapses. Thus, patients should be di-
agnosed and treated in an experienced 
multi-professional team, including 
pediatric intensive care providers, pedi-
atric radiologists, neuro-paediatricians, 
and pediatric rheumatologists/ immu-
nologists. To date, treatment regimens 
are based on case reports, small case 
collections, and expert opinions. Stud-
ies are urgently warranted, comparing 
applied treatment regimens, in order to 
ensure optimal treatment outcomes. We 
conclude that initial anticoagulation 
with unfractionated heparin, followed 
anti-platelet therapy with ASA and/or 
clopidogrel, in combination with im-
mune modulating treatment with high-
dose corticosteroids in the acute phase, 
followed by steroid-sparing mainte-
nance treatment with mycophenolate 
mofetil, may be effective and safe in 
childhood progressive pPACNS.
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